Tempus AI (NASDAQ:TEM) CEO Sells $9,556,050.00 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Eric Lefkofsky sold 166,250 shares of Tempus AI stock in a transaction on Monday, June 29th. The stock was sold at an average price of $57.48, for a total transaction of $9,556,050.00. Following the transaction, the chief executive officer directly owned 8,775,283 shares of the company’s stock, valued at $504,403,266.84. The trade was a 1.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Tempus AI Stock Performance

Shares of TEM opened at $60.27 on Friday. The company’s fifty day simple moving average is $50.48 and its 200-day simple moving average is $54.57. The company has a market cap of $10.82 billion, a P/E ratio of -35.04 and a beta of 3.46. The company has a current ratio of 3.31, a quick ratio of 3.15 and a debt-to-equity ratio of 2.96. Tempus AI, Inc. has a twelve month low of $41.73 and a twelve month high of $104.32.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.08. The firm had revenue of $348.12 million during the quarter, compared to analysts’ expectations of $345.44 million. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The firm’s revenue for the quarter was up 36.1% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.24) EPS. As a group, analysts expect that Tempus AI, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently made changes to their positions in TEM. JPL Wealth Management LLC bought a new position in Tempus AI during the 3rd quarter worth about $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Tempus AI in the 4th quarter valued at about $27,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Tempus AI in the 3rd quarter valued at about $38,000. Whittier Trust Co. lifted its position in shares of Tempus AI by 190.0% in the 1st quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after purchasing an additional 570 shares during the period. Finally, Lodestone Wealth Management LLC purchased a new stake in shares of Tempus AI in the 4th quarter worth approximately $42,000. 24.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. TD Cowen boosted their price objective on Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research note on Tuesday. HC Wainwright decreased their price objective on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating for the company in a report on Monday, May 11th. Guggenheim lowered their price objective on shares of Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a research report on Monday, March 30th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research report on Tuesday, June 2nd. They issued a “peer perform” rating for the company. Nine analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI presently has an average rating of “Hold” and an average price target of $68.54.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.